Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Newron Pharmaceuticals SpA의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Rand Worldwide Inc 주요 수익원은 Software and Hardware이며, 최신 수익 발표에서 수익은 330,701,000입니다. 지역별로는 United States and Canada이 Rand Worldwide Inc의 주요 시장이며, 수익은 408,105,000입니다.